HOME >> MEDICINE >> NEWS
Coronary heart disease risk assessment improves with coronary artery calcium scoring

TORRANCE, Calif. (January 14, 2004) -- In an article published in the January 14 edition of The Journal of the American Medical Association, researchers conclude that there is evidence that CT scans for calcium can play a significant role in predicting cardiac deaths and may assist physicians in making treatment decisions for the millions of people in the middle-range of coronary risk. The research study done at the South Bay Health Watch at the Research and Education Institute at Harbor-UCLA involved 1461 research volunteers in LA's south bay suburbs and was funded by the National Heart Lung and Blood Institute of the National Institutes of Health.

The South Bay Heart Watch findings support and confirm the recommendations of the American Heart Association/American College of Cardiology Consensus Group that selected use of CT scanning can assist in evaluating risk and determining appropriate preventative therapy in these persons.

Coronary artery calcium scans measure the amount of calcium buildup in the arteries of the heart. Calcium is one of many substances found in atherosclerotic plaques. The calcium score correlates with the amount and severity of blockages a person has.

According to the one of the study's authors, Robert C. Detrano, MD, PhD, "The findings are particularly significant because treatment decisions are the hardest to make for patients of middle risk. If a large amount of coronary calcium in such people is found to be an important predictor of future coronary disease, doctors might be able to make faster and more aggressive treatment decisions such as prescribing drugs or lifestyle changes." Dr. Detrano is a principal investigator at the Research and Education Institute and a Professor of Medicine in the Division of Cardiology at Harbor-UCLA Medical Center.


'"/>

Contact: Robert C. Detrano, MD,PhD
rdetrano@rei.edu
310-222-5290
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
15-Jan-2004


Page: 1

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. Coronary stents do not improve long-term survival
3. Coronary aneurysms are independent predictor of mortality, should be aggressively monitored
4. Coronary artery calcium can be a warning sign of fatal cardiac event
5. American Heart Association Comment: Contributions Of Trends In Survival And Coronary-Event Rates To Changes In Coronary Heart Disease Mortality
6. HbA1 Predicts Coronary Artery Disease In Female But Not Male Type 1 Diabetics, Says University Of Pittsburgh Researcher
7. Routine Use Of Coronary Stents Found To Yield Better Outcomes, Be More Cost-Effective
8. National Clinical Trial To Test Effectiveness Of Antibiotic Treatment For Coronary Artery Disease
9. New study in Nature demonstrates protection against cell death during heart attack
10. Uric acid and heart disease
11. Researchers search for first sign of congestive heart failure

Post Your Comments:
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As ... cancer continue to mount in courts throughout the U.S., ... Drug Administration (FDA) recently held a meeting to discuss ... as incretin mimetics. According to a June 12th ... from the makers of Januvia and similar drugs, following ...
(Date:6/19/2013)... In what is believed to be the largest follow-up ... hereditary dystonia a movement disorder that can cause ... report good success rates and lasting benefits. , Michele ... at Cedars-Sinai Medical Center,s Department of Neurology, and Ron ... at Beth Israel Deaconess Medical Center in Boston, published ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... The Movement Disorders Center ... urologists with specialists in physical therapy, occupational therapy ... and their family members to manage diseases and ... also have the opportunity to participate in the ... disorders can be relentlessly progressive and disabling conditions, ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
Cached News: